At the ADA conference, the weight loss drug "Hua Shan Competition" was performed, and Nobility and Jiang also faced off on stage.

Weight loss drug giants Eli Lilly (LLY.US), Novo Nordisk A/S Sponsored ADR Class B (NVO.US), and Amgen (AMGN.US) plan to announce the results of their major clinical trials at the 85th Annual Scientific Meeting of the American Diabetes Association (ADA) in Chicago from June 20th to 23rd. Eli Lilly will announce the results of its ongoing oral weight loss therapy (orforglipron) Phase 3 clinical trials for adult patients with type 2 diabetes on June 21st at a symposium hosted by ADA. The pharmaceutical company released the final data of the ACHIEVE-1 trial in April, indicating that this once-daily medication resulted in an average weight loss of about 8% for patients over a 40-week trial period. Novo Nordisk A/S Sponsored ADR Class B will also participate in a symposium on June 22nd to announce the data from the REDEFINE 1 and REDEFINE 2 Phase 3 clinical trials of their next-generation weight loss therapy CagriSema. The Danish pharmaceutical company's stock saw a significant decline in December due to the failure to meet initial expectations in their REDEFINE 1 trial, which recruited obese or overweight adults with other related conditions. The company stated before the event, "The presentation of the CagriSema REDEFINE 1 and 2 trials marks the first disclosure of Phase 3 clinical data on the combination of GLP-1 and amylin receptor agonists, providing important insights into the potential of this investigational drug." Meanwhile, the safety of Amgen's experimental weight loss therapy MariTide will be a focal point. The company will announce the complete data of a Phase 2 clinical trial on this injectable on June 23rd. Amgen's stock experienced a decline in November after reporting that MariTide resulted in an average weight loss of up to 20% in subjects over a 52-week trial period. The trial recruited individuals with obesity or overweight without type 2 diabetes. A report from Cantor Fitzgerald previously suggested that a potential decrease in bone mineral density could be a safety concern associated with the MariTide product, which targets GLP-1 and glucose-dependent insulinotropic peptide receptors. Other prominent weight loss drug development companies featured in the ADA meeting presentations include Altimmune (ALT.US), Metsera (MTSR.US), and Vertex Pharmaceuticals (VRTX.US).